TaILOR: a randomised trial to compare the clinical and cost-effectiveness of a patient-initiated follow-up (PIFU) strategy compared to standard care pathways in people with inflammatory arthritis: a s...

Background Inflammatory arthritis comprises lifelong conditions, such as rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis that require long-term treatment and regular monitoring. ...

link.springer.com

Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial

SRT can reduce ranibizumab treatment burden without compromising vision.

thelancet.com

EQ-5D vision bolt-on in macular degeneration: associations with visual measures and effect on utility differences and cost-effectiveness of stereotactic radiotherapy - Health and Quality of Life Outcomes

Background The UK STAR trial [Stereotactic Radiotherapy (SRT) for neovascular age-related macular degeneration (nAMD)] compared 16-Gray SRT (n = 274) with double-masked sham SRT (n = 137) in participants with chronic active nAMD. SRT reduced intravitreal anti-vascular endothelial growth factor (VEGF) re-treatments over two years of pro re nata ranibizumab, followed by two years of routine care. However, this resulted in worse best-corrected visual acuity (BCVA) in Years 3 and 4. This paper describes: associations between the EQ-5D vision bolt-on and visual acuity and patient-reported outcome measures; the impact of SRT on utilities with and without vision bolt-on; how the vision bolt-on affects the cost-effectiveness of SRT plus anti-VEGF versus anti-VEGF alone. Methods Using data from the entire STAR trial cohort, we compared mean BCVA, EQ-5D-5L, and Visual Function Questionnaire-25 (VFQ-25) scores across the three levels of the EQ-5D vision bolt-on. We examined the relationship between BCVA and EQ-5D (with/without the bolt-on) and VFQ-25. An economic evaluation estimated the cost-effectiveness of SRT from a UK national health service perspective over two years and over four years. This used prospective data on EQ-5D-5L and eye-related direct healthcare use. Results Participants reporting vision problems on the bolt-on had significantly worse BCVA, EQ-5D-5L, and VFQ-25 scores than those who did not. EQ-5D utilities (with and without the bolt-on) increased with BCVA but showed weaker correlations than VFQ-25 composite scores. Quality-adjusted life years (QALYs) did not differ significantly between treatment groups, with or without the bolt-on. The economic evaluation suggested SRT would reduce healthcare costs by £404 (95% CI: -£1282 to £2092) per patient at a four-year time horizon. The probability of SRT plus anti-VEGF being cost-effective at a £20,000 per QALY threshold was 65% at a four-year time horizon. Sensitivity analyses confirmed the robustness of incorporating the vision bolt-on did not alter the cost-effectiveness conclusion. Conclusions Resource use data from the trial and routine follow-up could be used for future economic models. The vision bolt-on captured quality of life differences between participants but may not be sufficiently responsive to visual acuity decline in trials where only one eye is treated. Trial registration ISRCTN12884465, registration date 01/12/2014.

doi.org

Patellar resurfacing in total knee replacement: 20-year clinical and economic results of a large multicentre, randomised controlled trial in the UK

There was no significant difference in primary outcome (OKS) or other clinical endpoints. However, as clinical differences tend to support patellar resurfacing, the resurfacing group had significantly...

thelancet.com

Stereotactic radiotherapy for neovascular age related macular degeneration: year 3 and 4 extended follow up results of a randomised, double masked, sham controlled, device trial (STAR)

Objective To assess the effects of stereotactic radiotherapy (SRT) for neovascular age related macular degeneration (AMD) beyond the two year primary outcome of the StereoTactic radiotherapy for wet A...

doi.org

Summer 2026: University of Glasgow – Health Economists' Study Group

hesg.org.uk

The cost and cost-effectiveness of whole-exome and whole-genome sequencing: a systematic literature review - European Journal of Human Genetics

European Journal of Human Genetics - The cost and cost-effectiveness of whole-exome and whole-genome sequencing: a systematic literature review

nature.com

Global income polarization: relative and absolute perspectives

rdcu.be

Public preferences for saving lives versus life-years: evidence from a person-trade-off experiment in 12 countries during the COVID-19 pandemic - The European Journal of Health Economics

The European Journal of Health Economics - Health technology assessment (HTA) often prioritises outcomes measured in life-years or Quality-Adjusted Life Years (QALYs), implying a focus on...

link.springer.com

Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial

The clinical benefits of intensity-modulated proton therapy (IMPT) compared with intensity-modulated radiation therapy (IMRT) for patients with oropha…

sciencedirect.com

Liquid biopsy for the diagnosis of EBV-positive Burkitt’s lymphoma in endemic areas - Nature Medicine

In clinical validation of a liquid biopsy assay, the approach enabled fast and accurate molecular diagnosis of EBV+ Burkitt’s lymphoma in more than 200 children and young adults in Tanzania and Uganda...

nature.com

Study with us: HERC Short Courses - 2026

Discover the courses and workshops, online and in-person, available for researchers, students and other professionals at the Health Economics Research Centre

herc.ox.ac.uk

Is liquid biopsy a cost-effective method to diagnose Burkitt Lymphoma in children and young adults? A health economic evaluation in Tanzania - BMC Medicine

Background Burkitt Lymphoma (BL) is a prevalent and highly aggressive childhood cancer in sub-Saharan Africa (SSA). Outcomes are poor, due in part to delays or inaccuracies in diagnosis. Liquid biopsy...

link.springer.com

Towards a Multi-sectoral Approach to Population Health: A Scoping Review of Cross-sectoral Evaluations of Health Interventions - Applied Health Economics and Health Policy

Background Health interventions, particularly those targeted at health promotion and disease prevention, often have a range of impacts that span beyond the healthcare sector. Making the case for inves...

link.springer.com

Interacting Decisions in Economic Evaluation and Health Technology Assessment : Online Workshop

herc.ox.ac.uk

Cost Effectiveness of Local Anaesthetic Transperineal Versus Transrectal Biopsy: Results from the TRANSLATE Study

A local anaesthetic ultrasound-guided transperineal prostate biopsy has a higher mean cost and no significant difference in mean quality-adjusted life years, compared with a transrectal ultrasound-gui...

eu-focus.europeanurology.com

herc.ox.ac.uk

Correspondence on “Parents’ perceptions of the utility of genetic testing in the NICU” by Callahan et al

sciencedirect.com

MSR176 Q-Squared as a Mapping Model Performance Metric in Gastrointestinal Disease

sciencedirect.com

EE588 Modeling Framework for Assessing Cost-Effectiveness of New Treatments in Chronic Kidney Disease

sciencedirect.com

P38 "Tell Me a Story": A Randomized Study Comparing Tabulated and Narrative Presentations of a Discrete Choice Experiment

sciencedirect.com

Supporting women with adherence to adjuvant endocrine therapy (SWEET): feasibility study of the HT&Me intervention

Women with estrogen receptor-positive breast cancer are recommended daily oral adjuvant endocrine therapy for at least 5 years, but up to 50% disconti…

sciencedirect.com

Q-Squared as a Mapping Model Performance Metric in Gastrointestinal Disease

ispor.org

HERC Webinar: Raphael Wittenberg - Financing Long-term Care

Online surveys is a powerful, easy to use tool for creating online surveys. Run by Jisc, online surveys is used by over 300 different organisations in the UK...

app.onlinesurveys.jisc.ac.uk

HERC database of mapping studies

herc.ox.ac.uk

WHO model for costing of blood products

iris.who.int